Pfizer Gets EU Approval For Nimenrix to Treat Invasive Meningococcal Disease in Infants

Pfizer said Monday that Nimenrix, a treatment for infants with invasive meningococcal disease, was approved by the European Commission for an expanded indication in the European Union.

The decision was made based on the company’s phase 3 trial of the drug, which looked at its impacts on 1,000 infants from six weeks of age. The drug was approved in a two dose primary series, with the first coming from six weeks old and an interval of two months between the dosages, with a booster at 12 months.

“With this approval, Nimenrix now has the broadest age indication of any conjugate vaccine in Europe against invasive meningococcal disease caused by Neisseria meningitidus serogroups A, C, W-135 and Y, to help protect people as young as six weeks of age,” said Luis Jodar, Pfizer’s chief medical and scientific affairs officer.

Leave a Comment